Velpatasvir

Velpatasvir is a cornerstone of modern hepatitis C therapy, offering a pan-genotypic cure for chronic HCV infection when used in combination with sofosbuvir. As a second-generation NS5A inhibitor, Velpatasvir demonstrates potency improvements of up to 33,000-fold and an improved resistance barrier relative to first-generation NS5A inhibitors such as ledipasvir. Velpatasvir is approved as part of the fixed-dose combination product Epclusa® (sofosbuvir/velpatasvir), which provides a simplified, interferon-free, ribavirin-free treatment regimen for all six major HCV genotypes. Velpatasvir acts on the crucial "membranous web" that facilitates HCV RNA replication, effectively disrupting viral replication and assembly. Beyond hepatitis C, Velpatasvir has also been investigated for activity against SARS-CoV-2, with in silico studies suggesting potential binding to the SARS-CoV-2 spike protein. Velpatasvir is supplied as a high-purity research compound (≥95%) and API for pharmaceutical manufacturing and analytical reference applications.

 

Product Parameters

---

Parameter	Specification
Product Name	Velpatasvir
CAS Number	1377049-84-7
Molecular Formula	C₄₉H₅₄N₈O₈
Molecular Weight	883.00 g/mol
Appearance	Light yellow solid
Melting Point	170℃
Density	1.314±0.06 g/cm3
Storage Condition	-20°C

 

Application

---

1. Vipatavir is an NS5A inhibitor for patients with hepatitis C virus (HCV) infection.

 

2. For the treatment of adult patients infected with hepatitis C virus types 1 to 6, it may be used alone in patients without cirrhosis or with compensated cirrhosis, and may also be combined with ribavirin for patients with decompensated cirrhosis.

 

3. Vipatavir is a second-generation NS5A inhibitor that exhibits potent antiviral activity in vitro against all HCV genotypes as well as common NS5A mutations and drug resistance mutations.

 

Bioactivity

---

Velpatasvir (GS-5816) is a second-generation NS5A inhibitor that inhibits the replication of hepatitis C virus (HCV).

Product Quality Assurance

---

Cosperpharm has established a comprehensive quality assurance system for Velpatasvir that meets the rigorous expectations of pharmaceutical manufacturing and analytical reference applications:

 

Thorough analytical characterization. Each batch undergoes multi-technique analytical release testing: HPLC purity verification (≥95% with full chromatographic traceability), appearance verification, identity confirmation, and residual solvent analysis.

 

Full batch traceability with retention samples. From raw material procurement through synthesis, purification, and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with retention samples maintained in accordance with Cosperpharm quality procedures.

 

Stability monitoring program. Cosperpharm conducts ongoing stability studies under recommended storage conditions (-20°C and 4°C). Stability summaries are available to support customer regulatory submissions.

 

Documentation ready for regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch-specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation. For customers preparing ANDA or NDA filings, Cosperpharm provides DMF-ready documentation packages, method validation reports, stability data, and custom quality agreements upon request.

 

Customer-initiated quality audits. Qualified customers are welcome to audit Cosperpharm's manufacturing, quality control, and documentation facilities. Please contact our regulatory team to schedule an audit.

 

Contact Us

---

Developing a generic version of a complex antiviral like Velpatasvir requires a partner who understands the importance of compound quality, regulatory documentation, and supply chain reliability. Cosperpharm delivers high-purity Velpatasvir with the analytical rigor and responsive service that pharmaceutical manufacturers need. Contact our team today to discuss your requirements, request a quote, or learn more about our documentation packages.